FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1.5_FITC_102110
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
  • GK1.5_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100405 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100406 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  2. Liu J, et al. 2021. Front Immunol. 12:747730. PubMed
  3. Su Y, et al. 2022. J Hematol Oncol. 15:99. PubMed
  4. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  5. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  6. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  7. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  8. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  9. Katsumura KR, et al. 2018. Proc Natl Acad Sci U S A. 115:E10109. PubMed
  10. Valanparambil RM, et al. 2017. PLoS Pathog. 13:e1006647. PubMed
  11. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  12. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  13. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  14. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  15. He R, et al. 2021. J Immunol. 206:2353. PubMed
  16. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  17. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  18. Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
  19. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  20. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  21. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  22. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  23. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  24. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  25. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  26. Jiang W, et al. 2022. Front Immunol. 13:878832. PubMed
  27. Toomer G, et al. 2022. Viruses. 14:. PubMed
  28. Sega E, et al. 2008. Int J Radiat Oncol Biol Phys. 71:559. PubMed
  29. Lua Y, et al. 2012. Mol Immunol. 52:229. PubMed
  30. Zasłona Z, et al. 2014. J Immunol. 193:4245. PubMed
  31. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  32. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  33. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  34. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  35. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  36. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  37. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  38. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  39. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  40. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  41. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  42. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  43. Pobezinskaya EL et al. 2019. Front Immunol. 1.079861111 . PubMed
  44. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  45. Aqel SI, et al. 2021. JCI Insight. 6:e142376. PubMed
  46. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  47. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  48. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  49. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  50. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  51. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  52. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  53. Guan H, et al. 2012. PLoS One. 7:e35650. PubMed
  54. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  55. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  56. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  57. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  58. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  59. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  60. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  61. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
  62. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  63. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  64. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  65. White C, et al. 2014. J Immunol. 193:5933. PubMed
  66. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  67. Thomas S, et al. 2019. J Immunother Cancer. 7:214. PubMed
  68. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  69. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  70. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  71. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  72. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
  73. Ren HZ, et al. 2022. J Clin Transl Hepatol. 10:1138. PubMed
  74. Ma X, et al. 2021. Cell Metabolism. 33(5):1001-1012.e5. PubMed
  75. Zongyi Y, et al. 2017. PLoS One. 10.1371/journal.pone.0189617. PubMed
  76. Raineri D, et al. 2021. Biomedicines. 10:. PubMed
  77. He X, et al. 2021. Small. 17:e2007165. PubMed
  78. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  79. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  80. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  81. Wang Z, et al. 2020. J Clin Invest. 130:3717. PubMed
  82. Pedraza–Zamora CP, et al. 2017. Parasite Immunol. 39:4. PubMed
  83. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  84. Wang Z, et al. 2022. Nat Biomed Eng. 6:791. PubMed
  85. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  86. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  87. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  88. Deng Z, et al. 2020. World J Gastrointest Oncol. 1091:12. PubMed
  89. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  90. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  91. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  92. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  93. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  94. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  95. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  96. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  97. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  98. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  99. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  100. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  101. Ahmari N, et al. 2016. Physiol Genomics. 48: 526 - 536. PubMed
  102. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  103. Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
  104. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  105. Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed
  106. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  107. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  108. Zhu Y, et al. 2021. EMBO J. 40:e105320. PubMed
  109. Wang Y, et al. 2021. Front Microbiol. 12:701566. PubMed
  110. Gebre MS, et al. 2022. NPJ Vaccines. 7:88. PubMed
  111. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  112. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  113. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  114. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  115. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  116. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  117. Sun H, et al. 2022. Front Immunol. 13:818017. PubMed
  118. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  119. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  120. Lang V, et al. 2021. Elife. 10:. PubMed
  121. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  122. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  123. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  124. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  125. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  126. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  127. Mencl S, et al. 2014. J Neuroimmunol. 274:125. PubMed
  128. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  129. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  130. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  131. Ma K, et al. 2022. iScience. 25:104347. PubMed
  132. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  133. Gao X, et al. 2022. Front Immunol. 13:799331. PubMed
  134. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  135. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  136. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  137. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  138. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  139. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  140. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  141. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  142. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  143. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  144. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  145. Takaku S, et al. 2022. Evid Based Complement Alternat Med. 2022:6122955. PubMed
  146. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  147. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  148. Li J, et al. 2020. Development. . PubMed
  149. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  150. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  151. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  152. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  153. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  154. Zan H, et al. 2017. Nat Commun. 8:14244. PubMed
  155. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  156. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  157. Reynolds CJ, et al. 2018. Sci Rep. 8:672. PubMed
  158. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  159. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  160. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  161. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  162. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  163. Ligon MM, et al. 2020. Mucosal Immunol. 1.172222222. PubMed
  164. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  165. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  166. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  167. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  168. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  169. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  170. Pan L, et al. 2022. Front Immunol. 13:837497. PubMed
  171. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  172. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  173. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  174. Liu Y, et al. 2020. Cell Death Dis. 11:1062. PubMed
  175. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  176. Khosravi N, et al. 2018. Cancer Immunol Res. 0.797222222. PubMed
  177. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  178. Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed
  179. Habtetsion T et al. 2018. Cell metabolism. 28(2):228-242 . PubMed
  180. Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed
  181. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  182. Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed
  183. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  184. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  185. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  186. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  187. Sears SM, et al. 2022. Kidney360. 3:818. PubMed
  188. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  189. Blaszczak AM, et al. 2020. Immunometabolism. 2:00. PubMed
  190. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  191. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  192. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  193. Zhao Y, et al. 2020. Front Immunol. 2.572222222. PubMed
  194. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  195. Wang Y, et al. 2022. Nat Commun. 13:1454. PubMed
  196. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  197. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  198. Li Z, et al. 2022. Evid Based Complement Alternat Med. 2022:7421265. PubMed
  199. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  200. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  201. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  202. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  203. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  204. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  205. Blaszczak AM, et al. 2019. J Immunol. 202:2451. PubMed
  206. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  207. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  208. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  209. Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
  210. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  211. Kathania M, et al. 2022. Cell Rep. 40:111345. PubMed
  212. Gawish R, et al. 2022. Elife. 11:. PubMed
  213. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  214. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  215. Gardenier J, et al. 2017. Nat Commun. 8:14345. PubMed
  216. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  217. Zeng A, et al. 2020. Oncol Rep. . PubMed
  218. Bartley A, et al. 2018. Front Physiol. 9:1593. PubMed
  219. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  220. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  221. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  222. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  223. Lestari SR, et al. 2020. J Ayurveda Integr Med. 11:414. PubMed
  224. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  225. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  226. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
  227. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  228. Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed
  229. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
RRID
AB_312690 (BioLegend Cat. No. 100405)
AB_312691 (BioLegend Cat. No. 100406)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC, IHC-F, ICC
FITC anti-mouse CD4 GK1.5 FC, IHC-F, ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC, IHC-F, ICC, IP, Costim, Block, Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC, IHC-F, ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC, IHC-F, ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC, ICC, IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC, Block, Costim, Depletion, IHC, IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F, FC, ICC, SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC, IHC-F, ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse CD4

  • Biotin anti-mouse CD4

  • FITC anti-mouse CD4

  • PE anti-mouse CD4

  • PE/Cyanine5 anti-mouse CD4

  • Purified anti-mouse CD4

  • PE/Cyanine7 anti-mouse CD4

  • APC/Cyanine7 anti-mouse CD4

  • Alexa Fluor® 647 anti-mouse CD4

  • Alexa Fluor® 488 anti-mouse CD4

  • Pacific Blue™ anti-mouse CD4

  • Alexa Fluor® 700 anti-mouse CD4

  • PerCP anti-mouse CD4

  • PerCP/Cyanine5.5 anti-mouse CD4

  • Brilliant Violet 421™ anti-mouse CD4

  • Ultra-LEAF™ Purified anti-mouse CD4

  • Alexa Fluor® 594 anti-mouse CD4

  • Brilliant Violet 711™ anti-mouse CD4

  • Brilliant Violet 510™ anti-mouse CD4

  • Brilliant Violet 605™ anti-mouse CD4

  • Brilliant Violet 785™ anti-mouse CD4

  • PE/Dazzle™ 594 anti-mouse CD4

  • APC/Fire™ 750 anti-mouse CD4

  • GoInVivo™ Purified anti-mouse CD4

  • Brilliant Violet 750™ anti-mouse CD4

  • Brilliant Violet 650™ anti-mouse CD4

  • Spark Blue™ 550 anti-mouse CD4

  • Spark NIR™ 685 anti-mouse CD4

  • KIRAVIA Blue 520™ anti-mouse CD4

  • PE/Fire™ 640 anti-mouse CD4

  • APC/Fire™ 810 anti-mouse CD4

  • PE/Fire™ 700 anti-mouse CD4

  • Spark Violet™ 538 anti-mouse CD4

  • Spark YG™ 593 anti-mouse CD4

  • Spark Blue™ 574 anti-mouse CD4 Antibody

  • Spark UV™ 387 anti-mouse CD4

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account